| Symbol | NUVB |
|---|---|
| Name | NUVATION BIO INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1500 BROADWAY,SUITE 1401, NEW YORK, New York, 10036, United States |
| Telephone | +1 332 208-6102 |
| Fax | — |
| — | |
| Website | https://www.nuvationbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001811063 |
| Description | Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The companys proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Additional info from NASDAQ: |
Mashal Robert 🟢 acquired 25.0K shares of Nuvation Bio Inc. (NUVB) at $4.73 Transaction Date: Jun 09, 2026 | Filing ID: 000004
Read moreVERNON W ANTHONY 🟢 acquired 123.4K shares (1 derivative) of Nuvation Bio Inc. (NUVB) at $4.79 Transaction Date: May 21, 2026 | Filing ID: 000003
Read moreMashal Robert 🟢 acquired 123.4K shares (1 derivative) of Nuvation Bio Inc. (NUVB) at $4.79 Transaction Date: May 21, 2026 | Filing ID: 000002
Read moreFALBERG KATHRYN E 🟢 acquired 123.4K shares (1 derivative) of Nuvation Bio Inc. (NUVB) at $4.79 Transaction Date: May 21, 2026 | Filing ID: 000006
Read moreBLICKENSTAFF KIM D 🟢 acquired 123.4K shares (1 derivative) of Nuvation Bio Inc. (NUVB) at $4.79 Transaction Date: May 21, 2026 | Filing ID: 000002
Read moreBazemore Robert B 🟢 acquired 123.4K shares (1 derivative) of Nuvation Bio Inc. (NUVB) at $4.79 Transaction Date: May 21, 2026 | Filing ID: 000003
Read moreCui Xiangmin 🟢 acquired 123.4K shares (1 derivative) of Nuvation Bio Inc. (NUVB) at $4.79 Transaction Date: May 21, 2026 | Filing ID: 000007
Read moreNew Form 4/A - Nuvation Bio Inc. <b>Filed:</b> 2026-05-26 <b>AccNo:</b> 0001487815-26-000006 <b>Size:</b> 6 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06841874 | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastati… | — | Lung Neoplasms | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positi… | Phase3 | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2025-08-21 | 2033-08-30 | ClinicalTrials.gov |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tum… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2024-03-14 | 2027-10-01 | ClinicalTrials.gov |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase3 | Glioma | Recruiting | 2023-06-05 | 2030-12-01 | ClinicalTrials.gov |
| NCT05609929 | Study the Effect of Omeprazole on AB-106 Pharmacokinetics | Phase1 | Pharmacokinetic Study | Completed | 2022-11-02 | 2023-01-20 | ClinicalTrials.gov |
| NCT05577416 | A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma | Early_Phase1 | Glioma | Completed | 2022-10-11 | 2025-03-26 | ClinicalTrials.gov |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | Phase1 | Prostate Cancer | Withdrawn | 2022-09-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT05191004 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Phase1 | Advanced Breast Cancer | Withdrawn | 2022-09-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adul… | Phase1 | Advanced Solid Tumor | Terminated | 2022-03-29 | 2024-07-15 | ClinicalTrials.gov |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | Phase2 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2021-09-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT05357820 | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itracon… | Phase1 | Solid Tumor | Completed | 2021-07-19 | 2021-12-03 | ClinicalTrials.gov |
| NCT05357911 | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin | Phase1 | Solid Tumor | Completed | 2021-07-13 | 2021-12-03 | ClinicalTrials.gov |
| NCT04617054 | Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fus… | Phase2 | Solid Tumor | Terminated | 2021-06-01 | 2024-12-06 | ClinicalTrials.gov |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and … | Phase1 | Glioma | Terminated | 2020-12-08 | 2022-08-31 | ClinicalTrials.gov |
| NCT04395677 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | Phase2 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2020-07-07 | 2027-06-01 | ClinicalTrials.gov |
| NCT02279433 | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetic… | Phase1 | Solid Tumors | Completed | 2014-09-01 | 2019-03-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| safusidenib | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Enzalutamide | Other | Phase PHASE1 | Prostate Cancer | WITHDRAWN | NCT05191017 |
| NUV-422 | Other | Phase PHASE1 | Prostate Cancer | WITHDRAWN | NCT05191017 |
| Fulvestrant | Other | Phase PHASE1 | Advanced Breast Cancer | WITHDRAWN | NCT05191004 |
| NUV-422 | Other | Phase PHASE1 | Advanced Breast Cancer | WITHDRAWN | NCT05191004 |
| NUV-422 | Other | Phase PHASE1 | Glioma | TERMINATED | NCT04541225 |
| Multiple administration of omeprazole Single administration of AB-106 | Other | Phase PHASE1 | Pharmacokinetic Study | COMPLETED | NCT05609929 |
| AB-106, digoxin | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357911 |
| AB-106, Rifampicin | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357820 |
| AB-106, Itraconazole | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357820 |
| DS6051b | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02279433 |
| NUV-1511 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06334432 |
| Part B: Safusidenib Erbumine | Other | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Surgery (maximal resection) | Procedure | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Part A: Safusidenib Erbumine | Other | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Biopsy | Other | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Enzalutamide | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| NUV-868 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| Taletrectinib | Other | Preclinical | Lung Neoplasms | NO_LONGER_AVAILABLE | NCT06841874 |
| Taletrectinib | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04919811 |
| AB-106 | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT04617054 |
| AB-106 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04395677 |
| Placebo | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| safusidenib | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Crizotinib | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT06564324 |
| NUV-1511 | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06334432 |
| Multiple administration of omeprazole Single administration of AB-106 | DRUG | Phase PHASE1 | Pharmacokinetic Study | COMPLETED | NCT05609929 |
| Part B: Safusidenib Erbumine | DRUG | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Surgery (maximal resection) | PROCEDURE | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Part A: Safusidenib Erbumine | DRUG | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Biopsy | PROCEDURE | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| AB-106, digoxin | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357911 |
| AB-106, Rifampicin | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357820 |
| AB-106, Itraconazole | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357820 |
| Placebo | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| safusidenib | DRUG | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| Olaparib | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| NUV-868 | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| Enzalutamide | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| Fulvestrant | DRUG | Phase PHASE1 | Advanced Breast Cancer | WITHDRAWN | NCT05191004 |
| Taletrectinib | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| NUV-422 | DRUG | Phase PHASE1 | Prostate Cancer | WITHDRAWN | NCT05191017 |
| AB-106 | DRUG | Phase PHASE2 | Solid Tumor | TERMINATED | NCT04617054 |
| Patient-reported outcomes (PROs) | OTHER | Preclinical | Cancer | RECRUITING | NCT04151342 |
| Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents. | DRUG | Preclinical | Cancer | RECRUITING | NCT04151342 |
| DS6051b | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02279433 |